Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/204225.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/202611.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4702.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4684.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4689.htm
Restrictions: First-line treatment of chronic lymphocytic leukaemia (CLL) in patients for whom fludarabine combination chemotherapy is not appropriate is restricted to use in accordance with regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/211004.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4691.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4693.htm
Restrictions: Restricted to specialist use only. The use in combination with other chemotherapy for conditioning prior to haematopoietic progenitor cell transplantation (HPCT) in haematological diseases or the treatment of solid tumours when high dose chemotherapy with HPCT support is appropriate is not recommended by SMC and is non-Formulary.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4697.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4699.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4678.htm
Restrictions: Use in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation is restricted to specialist use only in whom 90% or more of the tumour has been resected. Use as an adjunct to surgery in patients with recurrent histologically proved glioblastoma multiforme for whom surgical resection is indicated is restricted to specialist use only.
Prescribing Notes:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4680.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4682.htm
Restrictions: Restricted to specialist use only. Use in the treatment of ovarian cancer is restricted to use in accordance with regional protocol. It is not approved for the treatment of HIV-related Kaposi’s sarcoma, metastatic breast cancer or second line treatment for progressive multiple myeloma.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4711.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4714.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4719.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4721.htm
Restrictions:
Restricted to specialist use only in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4707.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4709.htm
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following:
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4711.htm
Restrictions: Restricted to specialist use only. Restricted to use for treatment of CLL in accordance with regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/27475.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4731.htm
Restrictions:
Restricted to specialist use only. Restricted to use only for bladder, pancreatic or lung cancer in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/37649.htm
Restrictions: Use in oncology is restricted to specialist use only. Oral use in the unlicensed indications of inflammatory bowel disease (see section 1.5) and autoimmune hepatitis is restricted to specialist initiation only in patients who fail to tolerate azathioprine.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4735.htm
Restrictions: Restricted to specialist use only. Use in the treatment of cancer is restricted to specialist use only, other indications require specialist initiation, but may be suitable for continuation by the GP.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4737.htm
Restrictions: Restricted to use only in patients in whom nelarabine is being used as a treatment to bridge to allogeneic stem cell transplant and restricted to use by specialists in haemato-oncology. It is not cost-effective when used for palliation.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/200049.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4740.htm
Restrictions: Use for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (SCT) with intermediate-2 and high-risk myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) is restricted to specialist use in accordance with regional protocol, which excludes the routine use in chronic myelomonocytic leukaemia (CMML).
Prescribing Notes:
The regional protocol for azacitadine for intermediate-2 and high-risk myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) is available here
The treatment of adults aged 65 years or older who are not eligible for haematopoitec stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% bone marrow blasts is not recommended for use in NHSScotland by the SMC and is non-Formulary.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/202606.htm#_202606
Restrictions:
Restricted to use in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106025.htm
Restrictions:
Restricted to specialist use only. Restricted to use in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/36783.htm
Restrictions: Restricted to specialist use only.
Prescribing Notes:
Excludes liposomal formulations.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4726.htm
Prescribing Notes:
The following indications are formulary but use is restricted to specialists and according to regional protocols:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/129178.htm
Restrictions: Use in adults for the treatment of advanced gastric cancer in combination with cisplatin is restricted to specialist use in accordance with regional protocol.
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4756.htm
Restrictions: Restricted to specialist use only. Restricted to use in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/65135.htm
Restrictions: Restricted to specialist use only.
Prescribing Notes:
Excludes Etopophos®
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4748.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4750.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4753.htm
Restrictions: Cetuximab may be used by specialists in accordance with regional protocol for the indications and restrictions listed in the prescribing notes section below:
Prescribing Notes:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/129183.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11766.htm
Restrictions: Restricted to specialist use only.
Prescribing Notes:
Alternative name: asparaginase
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11770.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11773.htm
Restrictions: Restricted to specialist use only. Use for adjuvant and metastatic breast cancer, metastatic prostate cancer, non-small cell lung cancer and cancer of the head and neck is restricted to use in accordance with regional protocols. The use of docetaxel in metastatic gastric adenocarcinoma has not been accepted by SMC and remains non-Formulary.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/39251.htm
Restrictions: Restricted to specialist use only. Excludes Siklos® which is not recommended for use by the SMC.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11776.htm
Restrictions: Restricted to use in accordance with regional protocols (see prescribing notes for Formulary indications)
Prescribing Notes:
Imatinib is Formulary in accordance with the restrictions above for the following indicaitons in adults:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106029.htm
Restrictions: Restricted to specialist use only. Restricted to use in the treatment of colorectal cancer in accordance with regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/60755.htm
Restrictions: Restricted to specialist use only. Restricted to use in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/81882.htm
Restrictions: Restricted to specialist use in accordance with regional protocol for chronic myelogenous leukaemia (CML).
Prescribing Notes:
The regional protocol for the use of nilotinib in CML is available here
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/200921.htm
Restrictions: Restricted to specialist use only as outlined in the Prescribing Notes below.
Prescribing Notes:
Restricted to use in the treatment of lung cancer (click here for protocol), ovarian cancer (click here for protocol) and metastatic breast cancer (click here for protocol) only in accordance with regional protocols.
Use in the treatment of AIDS related Kaposi’s sarcoma is non-Formulary.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/21851.htm
Restrictions: Restricted to use by specialists in haematological oncology for patients with hairy cell leukaemia.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11781.htm
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11787.htm
Restrictions: Restricted to use in accordance with regional protocol. The treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults is restricted to use in accordance with regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/129971.htm
Restrictions: Specialist use only in accordance with regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/77218.htm
Restrictions: Restricted to specialist use only. Restricted to use in the treatment of ovarian and cervical cancer in accordance with regional protocols. Monotherapy for the treatment of adult patients with relapsed small cell lung cancer is restricted to use according to regional protocol, however it should be noted that the IV formulation is non-Formulary for this indication.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/60767.htm
Restrictions: Restricted to specialist use only. Restricted to use in accordance with regional protocols.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/65167.htm
Restrictions: This is an orphan product and restricted to specialist initiation.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106417.htm
Restrictions: First-line treatment of advanced renal cell carcinoma (RCC) should be in accordance with regional protocol.
Prescribing Notes:
The following indications are not recommended for use by SMC and are non-Formulary
For the relevant SMC advice click here
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/208714.htm
Restrictions: Restricted to use in accordance with regional protocols (see prescribing notes for Formulary indications).
Prescribing Notes:
Erlotinib is Formulary in accordance with the restrictions above for the following indications:
Erlotinib is not recommended (and non-Formulary) for the following indications:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/129403.htm
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following:
Breast Cancer:
Restrictions: Use as monotherapy for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) is restricted to specialist use in accordance with regional protocol.
Prescribing Notes:
Use of afatinib for monotherapy of advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy is not recommended for use by the SMC and is non-Formulary.
Restrictions: In combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin containing regimen. It is restricted to specialist use in accordance with regional protocol.
Prescribing Notes:
For the relevant regional protocol please click here
Restrictions:
Restricted, as monotherapy, to first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in accordance with regional protocol click here (NHS network access required).
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_551819784
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11754.htm
Restrictions:
Restricted to specialist use only in accordance with regional protocol for the indication listed below:
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_535789330
Restrictions:
Restricted to specialist use in accordance with regional protocols.
Restrictions:
The following indication is restricted to specialist use only in accordance with regional protocol and treatment is subject to a two-year stopping rule:
Prescribing Notes:
Not recommended by SMC:
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_147626763
Restrictions:
Use as monotherapy for the treatment of adults with metastatic Merkel cell carcinoma (MCC) is restricted to specialist use in accordance with regional protocol click here (NHS network access required).
Restrictions: Restricted to specialist use in accordance with regional protocol.
Prescribing Notes:
The Regional Protocol can be accessed here (NHS network access required)
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP18848-axitinib.htm
Restrictions:
Restricted to specialist use in accordance with regional protocol only for the following indications:
Prescribing Notes:
Restrictions: Restricted to specialist use for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) in accordance with regional protocol (in development).
Restrictions: Restricted to specialist use according to regional protocols.
Prescribing Notes:
The following indications are Formulary for bortezomib in accordance with regional protocols:
For the NICE advice regarding bortezomib for multiple myeloma click here
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/128313.htm
Restrictions:
Use in the treatment of adults with Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate, is restricted to specialist use in accordance with regional protocol.
Prescribing Notes:
The treatment of adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) is not recommended by SMC and is non-Formulary.
BNF Link: https://www.medicinescomplete.com/mc/bnf/current/PHP33921-bosulif.htm#PHP33921-bosulif
Restrictions:
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, is restricted to specialist use in accordance with regional protocol (see link below).
Prescribing Notes:
The following indications are not recommended by the SMC and are non-Formulary:
Restrictions:
Restricted to specialist use in accordance with regional protocols for the following:
Restrictions:
Use in combination with prednisolone ir prednisone for the treatment of hormone refractory metastatic prostate cancer is restricted to specialist use in patients who have received at least 225mg/m2 (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 in accordance with regional protocol click here (NHS network access required).
Restrictions:
Restricted to specialist use in accordance with regional protocol - click here.
Prescribing Notes:
The following indications are not recommended for use by the SMC and are non-Formulary:
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_844159290
Restrictions: Restricted to specialist use only.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/11760.htm
Restrictions:
Use in combination with dexamethason for the treatment of adults with multiple myeloma who have received at least one prior therapy is restricted to specialist use in accordance with regional protocol - click here for protocol.
Restrictions:
Restricted to specialist use in accordance with regional protocol in adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Prescribing Notes:
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following indications:
Restrictions:
Restricted to specialist use in accordance with regional protocols for the following indications:
Prescribing Notes:
The following indications are not recommended for use by the SMC and are non-Formulary:
Restrictions:
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations, is restricted to specialist use only in accordance with regional protocol (click here, NHS network access required).
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_478115391
Restrictions:
Multiple Myeloma:
Prescribing Notes:
The following indications are not recommended by SMC and are non-Formulary:
Multiple Myeloma: In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (non-Submission to SMC).
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following:
Prescribing Notes:
The following indications are not recommended by the SMC and are non-Formulary:
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following:
Restrictions:
Restricted to use specialist use in accordance with regional protocol for locally advanced or metastatic breast cancer in adult patients who have progressed after at least two chemotherapeutic regimen for advanced disease- please click here for regional protocol.
Prescribing Notes:
Non-formulary indication:
Restrictions:
The following oncology indications are formulary but restricted to specialist use in accordance with regional protocols:
The following other indication(s) are restricted to specialist use only:
Prescribing Notes:
The following indications have not been accepted by SMC and remain non-Formulary:
Restrictions: Restricted to specialist use in accordance with regional protocol (in development) in patients with previously untreated locally advanced or metastatic NSCLC with activating EGFR-TK mutations i.e. as a first-line therapy.
Restrictions:
Restricted to specialist use in accordance with regional protocols for the following indications:
Prescribing Notes:
Ibrutinib remains non-Formulary for the following indications:
Restrictions: Restricted to specialist use in accordance with regional protocols (under development) for the indications outlined in the prescribing notes below.
Prescribing Notes:
Non-formulary indication:
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following indications:
Restrictions: Restricted to specialist use in adult patients with advanced (unresectable or metastatic) melanoma as first-line therapy and in adults who have received prior therapy.
Prescribing Notes:
The Regional Protocol can be accessed here (NHS network access required)
Restrictions:
Restricted to specialist use only in accordance with regional protocol for the following:
Restrictions:
Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults is restricted to specialist use only in accordance with regional protocol click here.
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following indications:
Prescribing Notes:
Use as monotherapy for the treatment of adults with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm or mast cell leukaemia is not recommended by SMC and is non-Formulary.
Restrictions: Please see under prescribing notes below.
Prescribing Notes:
Use in combination with docetaxel for the treatment of adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy is restricted to specialist use in accordance with regional protocol click here.
Restrictions:
Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy is restricted to specialist use only in accordance with regional protocol (click here) in patients who do not have a germline BRCA mutation.
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_518038795
Restrictions:
Restricted to specialist use in accordance with relevant regional protocols for the following indications:
Prescribing Notes:
Nivolumab is currently non-formulary for the following indications:
Restrictions: Restricted to specialist use in accordance with regional protocol (in development) as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Restrictions:
Use in combination with doxorubicin as a first-line treatment for advanced soft-tissue sarcoma that is not amenable to curative treatment with surgery or radiotherapy is restricted to specialist use in accordance with regional protocol.
Prescribing Notes:
Click here for regional protocol for treatment of soft-tissue sarcoma
Restrictions:
Treatment of adult patients with locally advanced or metastatic epidermal groth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) is restricted to specialist use in accordance with regional protocol (in development) in patients who have received previous treatment with an EGFR tyrosine kinase inhibitor.
Prescribing Notes:
Non-formulary indication:
Restrictions: Restricted to specialist use in accordance with regional protocol (see below) for the first-line treatment of adults with metastatic adenocarcinoma of the pancreas. First-line use with carboplatin in non-small cell lung cancer is not recommended by SMC and is non-Formulary.
Prescribing Notes:
Regional protocol for the first-line treatment of adults with metastatic adenocarcinoma of the pancreas click here.
Restrictions:
Restricted to specialist use in accordance with regional protocols for the indications listed below.
Prescribing Notes:
Restrictions:
The following indications are restricted to specialist use in accordance with regional protocol:
Prescribing Notes:
For relevant NICE advice please click here
Restrictions: Restricted to specialist use in accordance with regional protocol as part of combination treatment in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
Restrictions:
Restricted to specialist use in accordance with regional protocols:
Prescribing Notes:
Not recommended by SMC:
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_988968089
Restrictions:
Restricted to specialist use in accordance with relevant regional protocol for the following indication:
Prescribing Notes:
Non-formulary indication:
Restrictions: Restricted to specialist use in accordance with regional protocol for the indications listed in the Prescribing Notes below
Prescribing Notes:
Chronic myeloid leukaemia (CML):
The treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) in adults:
Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)
The treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia in adults:
To access the regional protocol click here
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following indications:
Prescribing Notes:
Non-Formulary indications:
BNF Link: https://www.medicinescomplete.com/mc/bnf/current/PHP34180-stivarga.htm#PHP34180-stivarga
Restrictions:
Restricted to specialist use in accordance with regional protocol in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy. Protocol can be accessed here (NHS network access required).
Restrictions: For restrictions see prescribing notes below.
Prescribing Notes:
Restricted to specialist use in accordance with regional protocol for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.
Non-formulary indication:
Treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
BNF Link: https://www.medicinescomplete.com/mc/bnf/current/PHP18721-jakavi.htm#PHP18721-jakavi
Restrictions: For restrictions please see prescribing notes below.
Prescribing Notes:
Hepatocellular carcinoma:
Restrictions:
First-line treatment of adult patients with advanced renal cell carcinoma (RCC) is restricted to specialist use only in accordance with regional protocol click here (NHS network access required).
BNF Link: https://www.medicinescomplete.com/#/content/bnf/_553353876
Restrictions:
In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation is restricted to specialist use and as 1st line treatment option in accordance with regional protocol (in development).
Prescribing Notes:
Non-Formulary indications:
Restrictions: Restricted to specialist use only for the indications listed in the Prescribing notes below.
Prescribing Notes:
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/88513.htm
Restrictions:
Restricted to specialist use in accordance with regional protocol for the following indications:
Restrictions:
Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents is restricted to specialist use in accordance with regional protocol - click here for protocol
Restrictions: Restricted to specialist use for first-line treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma pending regional protocol.
BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP17983-vemurafenib.htm
Restrictions:
The following indication is restricted to specialist use in accordance with regional protocols (click here, NHS network access required):